Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Wet AMD affects an estimated 1.5 to 2 million Americans with roughly 200,000 new cases diagnosed each year. Anti-VEGF therapy with ranibizumab, aflibercept,…
AbbVie said it would pay REGENXBIO $370 million upfront and up to $1.38 billion in additional payments for rights to develop and commercialize RGX-314, a gene…
REGENXBIO announced (Oct 6, 2025) completion of enrollment in the ATMOSPHERE and ASCENT pivotal trials of subretinal surabgene lomparvovec (sura-vec,…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
AbbVie and REGENXBIO entered a global eye care collaboration to develop and commercialize RGX-314 (now ABBV-RGX-314 / surabgene lomparvovec, "sura-vec"), a one-time AAV8 gene therapy expressing an anti-VEGF antibody fragment, for wet AMD, diabetic retinopathy and other chronic retinal diseases. Announced September 13, 2021 and closed November 9, 2021, REGENXBIO received $370M upfront and is eligible for up to $1.38B in development, regulatory and commercial milestones, with 50/50 US profit sharing and tiered ex-US royalties; AbbVie leads global development and commercialization. Post-close the program has advanced materially: the wet AMD pivotal trials ATMOSPHERE and ASCENT completed enrollment (Oct 2025, >1,200 patients, the largest gene-therapy program in nAMD to date) with topline data expected in 2026. On August 5, 2025 the parties amended the agreement — in lieu of a prior $200M milestone, AbbVie will pay REGENXBIO $100M on first patient dosed in the suprachoroidal DR Phase IIb/III trial and a further $100M on first patient dosed in a subsequent Phase III trial, while AbbVie independently funds a new wet AMD Phase III trial (ACHIEVE).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / REGENXBIO Inc. (this deal) | 2021 | $1.8B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2021 deals · AbbVie Inc. deals · Metabolic deals